
Bactiguard Holding
30.3
SEK
-0.98 %
Less than 1K followers
BACTI B
NASDAQ Stockholm
Medical Equipment & Services
Health Care
Overview
Financials & Estimates
Ownership
-0.98%
-0.66%
-14.16%
-8.18%
-52.66%
-58.09%
-73.61%
-64.6%
-3.81%
Bactiguard is a global MedTech company that prevent infections related to medical devices. The technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation. Bactiguard operates through license partnerships with MedTech companies that apply the technology to their medical devices. The company also has a portfolio of wound management products. Bactiguard has its headquarters in Stockholm.
Read moreMarket cap
1.06B SEK
Turnover
59.76K SEK
Revenue
241.68M
EBIT %
-11.94 %
P/E
-
Dividend yield-%
-
Financial calendar
24.4
2025
Interim report Q1'25
15.5
2025
General meeting '25
15.7
2025
Interim report Q2'25
ShowingAll content types

Carnegie Access: Bactiguard: New financial targets look more realistic
Bactiguard Holding AB (publ): Bactiguard announces updated strategic and financial targets
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Carnegie Access: Bactiguard: Solid Q4, but poor visibility for future growth drivers

Bactiguard, Audiocast with teleconference, Q4'24
Carnegie Access: Bactiguard: Higher sales than expected in Q4, but no news on financial targets
Bactiguard Holding AB (publ): Bactiguard Holding AB's year-end report 2024
Bactiguard Holding AB (publ): Invitation to presentation of Bactiguard's year-end report for 2024
Carnegie Access: Waiting for new long-term targets to be announced – Q4 preview
Carnegie Commissioned Research: Bactiguard: More needed for the share price to lift
Bactiguard Holding AB (publ): Nomination Committee appointed for Bactiguard Holding AB's Annual General Meeting 2025

Bactiguard, Audiocast with teleconference, Q3'24
Carnegie Commissioned Research: Bactiguard: Bactiguard (CR) Q3 deviation - Solid top-line growth
Bactiguard Holding AB (publ): Bactiguard Holding AB's interim report third quarter 2024
Bactiguard Holding AB (publ): Invitation to presentation of Bactiguard's interim report for the third quarter 2024
Carnegie Commissioned Research: Bactiguard: Higher risk in Zimmer Biomet agreement – Q3 preview
Bactiguard Holding AB (publ): Zimmer Biomet terminates agreement for multiple orthopedic product segments - trauma agreement remains in effect
Carnegie Commissioned Research: Bactiguard: Better than expected Q2 driven by higher licence revenue
